Talking Drug Development | GenomeWeb

At R&D Directions Insider, Michael Christel speaks with Bert Spilker, who has worked at a variety of drug companies and has written books on drug development, about mergers and acquisitions, clinical trial reform, transparency, and more. "The issue of transparency has been focused on the industry, and during the '90s and early part of this decade, the industry fought this quite strongly," Spilker says, adding that industry's position has changed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.